Oncology Drugs - Baltics | Statista Market Forecast

The Baltics is projected to witness significant revenue growth in the Oncology Drugs market.
By 2024, the market is expected to reach US$164.20m.
Furthermore, it is anticipated that the market will exhibit a CAGR of 7.09% between 2024 and 2029, resulting in a market volume of US$231.30m by 2029.
When compared on a global scale, United States is forecasted to generate the highest revenue in this market, with a projected amount of US$103.90bn in 2024.
The Baltics have experienced a surge in the development of innovative oncology drugs, positioning the region as a key player in the global pharmaceutical market.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

Treatment for different types of cancer, including skin cancer, leukemia, lymphoma, and multiple myeloma
Chemotherapeutic agents
Immuno-oncology drugs
Oncology orphan drugs

Radiation therapy
Medical devices

The Oncology Drugs market in Baltics has shown significant growth in recent years.

Customer preferences: Customers in Baltics have become increasingly aware of the importance of early detection and treatment of cancer. This has led to a higher demand for oncology drugs and a shift towards more targeted therapies. Patients and healthcare professionals are looking for drugs that have fewer side effects and are more effective in treating specific types of cancer.

Trends in the market: The oncology drugs market in Baltics has been growing steadily due to the increasing prevalence of cancer and the aging population. The market is dominated by multinational pharmaceutical companies, but local players are also gaining traction. The market is expected to continue to grow due to the development of new drugs and the increasing demand for targeted therapies. However, the market is also becoming more competitive, with the entry of biosimilars and generics.

Local special circumstances: Baltics has a relatively small population, which means that the market for oncology drugs is also relatively small. However, the market is highly concentrated, with a few large hospitals and clinics accounting for a significant portion of the demand. This concentration has led to a high level of competition among drug manufacturers and a focus on developing drugs that are more effective and have fewer side effects.

Underlying macroeconomic factors: Baltics has a relatively stable economy, with a growing healthcare sector. The government has been investing in healthcare infrastructure and increasing access to healthcare services. However, there are also challenges, such as an aging population and a shortage of healthcare professionals. These factors are expected to drive demand for oncology drugs in the region. Additionally, the region's membership in the European Union has led to increased access to new drugs and technologies, which is expected to further drive growth in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Cancer is one of the leading causes of death worldwide, with lung cancer alone ranked the sixth leading cause of death in 2021. Cancer, also known as malignant tumors and neoplasms, is the result of interactions between personal genetic factors and external agents causing abnormal transformations of cells into tumors over time. As the global population has increased in age, the incidence of new cancer cases has also risen, contributing to a higher number of deaths each year. In 2022, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 15 million by 2040.